Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase |
| |
Authors: | Cumming John G McKenzie Caroline L Bowden Stuart G Campbell Douglas Masters David J Breed Jason Jewsbury Philip J |
| |
Institution: | AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK. john.cumming@astrazeneca.com |
| |
Abstract: | SAR studies led to the identification of 4-(3-benzoylamino-6-methyl-anilino)quinazolines as potent and selective inhibitors of p38 MAP kinase. Further optimisation led to the identification of a series of 4-(3-benzoylamino-6-methyl-anilino)pyrimidines as potent inhibitors of the p38 MAP kinase signalling pathway in vitro and in vivo. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|